Cytogen's OncoScint OV103
Executive Summary
FDA grants orphan status to the monoclonal antibody-based diagnostic imaging agent for ovarian cancer. The product is currently in Phase III studies at 25 sites in the U.S. Cytogen says it expects to complete trials and file a PLA in early 1990.